- Home
- NYC vs DYAI Comparison
NYC vs DYAI Comparison
Compare NYC & DYAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NYC
- DYAI
- Stock Information
- Founded
- NYC 2013
- DYAI 1979
- Country
- NYC United States
- DYAI United States
- Employees
- NYC N/A
- DYAI N/A
- Industry
- NYC Real Estate
- DYAI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NYC Finance
- DYAI Health Care
- Exchange
- NYC Nasdaq
- DYAI Nasdaq
- Market Cap
- NYC 24.9M
- DYAI 29.6M
- IPO Year
- NYC N/A
- DYAI 2004
- Fundamental
- Price
- NYC $12.62
- DYAI $1.00
- Analyst Decision
- NYC
- DYAI Strong Buy
- Analyst Count
- NYC 0
- DYAI 1
- Target Price
- NYC N/A
- DYAI $6.00
- AVG Volume (30 Days)
- NYC 6.2K
- DYAI 38.9K
- Earning Date
- NYC 08-08-2025
- DYAI 08-12-2025
- Dividend Yield
- NYC N/A
- DYAI N/A
- EPS Growth
- NYC N/A
- DYAI N/A
- EPS
- NYC N/A
- DYAI N/A
- Revenue
- NYC $58,397,000.00
- DYAI $3,554,344.00
- Revenue This Year
- NYC $8.40
- DYAI $22.56
- Revenue Next Year
- NYC $1.62
- DYAI $30.95
- P/E Ratio
- NYC N/A
- DYAI N/A
- Revenue Growth
- NYC N/A
- DYAI 57.59
- 52 Week Low
- NYC $7.55
- DYAI $0.91
- 52 Week High
- NYC $13.60
- DYAI $2.20
- Technical
- Relative Strength Index (RSI)
- NYC 62.16
- DYAI 49.34
- Support Level
- NYC $8.85
- DYAI $0.95
- Resistance Level
- NYC $10.50
- DYAI $1.06
- Average True Range (ATR)
- NYC 0.85
- DYAI 0.06
- MACD
- NYC 0.35
- DYAI 0.01
- Stochastic Oscillator
- NYC 79.66
- DYAI 56.67
About NYC American Strategic Investment Co.
American Strategic Investment Co is an externally managed company that currently owns a portfolio of commercial real estate located within the five boroughs of New York City, majorly Manhattan. The Company's real estate assets consist of office properties and certain real estate assets that accompany office properties, including retail spaces and amenities.
About DYAI Dyadic International Inc.
Dyadic International Inc is a worldwide biotechnology platform company. It has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1.